SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Heidenreich A, Bolla M, Joniau S et al. EAU Guidelines on Prostate cancer 2011. Available at: http://www.uroweb.org/gls/pdf/08_Prostate_Cancer%20September%2022nd%202011.pdf. Accessed July 2012
  • 2
    Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 175664
  • 3
    Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 4
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 5
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 114754
  • 6
    Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (Suppl.): 1098109
  • 7
    Dahut W, Gulley J, Arlen P et al. Randomized phase II trial of docetaxel plus thalidomide in androgen independent prostate cancer. J Clin Oncol 2004; 22: 25329
  • 8
    Ning Y, Gulley J, Arlen P et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 20706
  • 9
    Scher HI, Jia X, Chi K et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29: 21918
  • 10
    Oh W, Halabi S, Kelly W et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003; 98: 25928
  • 11
    Picus J, Halabi S, Kelly WK et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011; 117: 52633
  • 12
    Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 2425
  • 13
    Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 27637
  • 14
    Ansari J, Choo B, Hussain A et al. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: An updated analysis. 2009 GU ASCO meeting, abstract 185.
  • 15
    Horwich A, Parker C, Bangma C et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol 2010; 21 (Suppl. 5): v12933
  • 16
    Yasufuku T, Shigemura K, Matsumoto O, Arakawa S, Fujisawa M. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. J Infect Chemother 2010; 16: 2005
  • 17
    Petrioli R, Pascucci A, Conca R et al. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer 2011; 104: 6139
  • 18
    Beer TM, Hough KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001; 28 (Suppl. 15): 4955
  • 19
    Small EJ, Schellhammer PF, Higano CS et al. Placebo controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 308994
  • 20
    Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 41122
  • 21
    Higano C, Schellhammer P, Small E et al. Integrated data from 2 controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 36709
  • 22
    Higano C, Corman J, Smith D et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 97584
  • 23
    Small E, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 388391
  • 24
    Small E, Demkow T, Gerritsen WR et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20295. Accessed July 2012
  • 25
    Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20543. Accessed July 2012
  • 26
    Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 71123
  • 27
    Fong L, Kwek SS, O’Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 60915
  • 28
    Beer TM, Slovin SF, Higano CS et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008; 26 (Suppl.): abstract 5004
  • 29
    Hodge JW, Greiner JW, Tsang KY et al. Co-stimulatory molecules as adjuvants for immunotherapy. Front Biosci 2006; 11: 788803
  • 30
    Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099105
  • 31
    Coleman RE. Skeletal complications of malignancy. Cancer 1997; 8 (Suppl.): 158894
  • 32
    Clarke NW, Fleisch H. Biology of bone metastases and the role of bisphosphonates. In: Ablin RJ, Mason M eds, Cancer Metastasis: Biology and Treatment. The Netherlands: Springer, 2007, pp. 25382
  • 33
    Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 87982
  • 34
    Clarke NW. Bisphosphonates: do we have a toxicity problem? Eur Urol 2008; 54: 9745
  • 35
    Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 12218
  • 36
    Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 156471
  • 37
    Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 81322
  • 38
    Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 3946
  • 39
    Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999; 52: 11121
  • 40
    van der Linden YM, Lok JJ, Steenland E et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004; 59: 52837
  • 41
    Papatheofanis FJ, Smith C, Najib M. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. Am J Ther 2009; 16: 12732
  • 42
    Baczyk M, Milecki P, Baczyk E, Sowiński J. The effectiveness of strontium 89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil 2003; 5: 3648
  • 43
    Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol 1993; 20 (Suppl. 2): 3843
  • 44
    Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 3340
  • 45
    Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44: 51926
  • 46
    Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 157481
  • 47
    Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 9405
  • 48
    Nilsson S, Franzén L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 58794
  • 49
    Parker C, Heinrich D, O'Sullivan JM et al. Overall survival benefit of radium-223 chloride (AlpharadinTM) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47 (Suppl. 2): 3
  • 50
    Tu S-M, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 33641
  • 51
    ClinicalTrials.gov. Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00554918?term=trapeze+trial&rank=2. Accessed July 2012
  • 52
    Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 1106
  • 53
    Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273: 1258492
  • 54
    Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 247887
  • 55
    Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the eYcacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 195966
  • 56
    James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 111223
  • 57
    ClinicalTrials.gov. A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0). Available at: http://clinicaltrials.gov/ct2/show/NCT00626548. Accessed July 2012
  • 58
    George D, Halabi S, Shepard T et al. Prognostic signifi cance of plasma vascular endothelial growth factor levels in patients with hormone refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 19326
  • 59
    Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 31924
  • 60
    Ogita S, Tejwani S, Heilburn LK et al. Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol 2011; 29 (Suppl. 7): abstract 33
  • 61
    Kelly WK, Halabi S, Carducci MA et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:153440
  • 62
    Cooper CS. The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. Oncogene 1992; 7: 37
  • 63
    Hussain M, Smith MR, Sweeney C et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29 (Suppl.): abstract 4516
  • 64
    Yu E, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 74218
  • 65
    Araujo J, Armstrong AJ, Braud EL et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009; 27 (Suppl.): abstract 5061
  • 66
    Miyake H, Nelson C, Rennie PS et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 1706
  • 67
    Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 327684
  • 68
    Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 165563
  • 69
    Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 424754
  • 70
    Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101: 22757
  • 71
    Garrido C, Ottavi P, Fromentin A et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57: 26617
  • 72
    Rocchi P, So A, Kojima S et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595602
  • 73
    Rocchi P, Jugpal P, So A, Sinneman S et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006; 98: 10829
  • 74
    Chi KN, Hotte SJ, Ellard S et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol 2012; 30 (Suppl. 5): abstract 121